New insights into the anti-inflammatory mechanisms of glucocorticoids: An emerging role for glucocorticoid-receptor-mediated transactivation

Endocrinology

Volumn 154, Issue 3, 2013, Pages 993-1007

  Vandevyver, Sofie ^a,b   Dejager, Lien ^a,b   Tuckermann, Jan ^c   Libert, Claude ^a,b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b Department of Biomedical Molecular Biology ^*  (Belgium)

^c UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A3 RECEPTOR; CD163 ANTIGEN; CELL ADHESION MOLECULE; CLARA CELL PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1C; CYCLOOXYGENASE 2; EOTAXIN; FORMYLPEPTIDE RECEPTOR; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 6; KRUPPEL LIKE FACTOR 2; LIPOCORTIN 1; MACROPHAGE INFLAMMATORY PROTEIN; MICROSOMAL AMINOPEPTIDASE; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; RANTES; RGS2 PROTEIN; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR FOXP3;

ANTIINFLAMMATORY ACTIVITY; GENE EXPRESSION PROFILING; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW; TRANSACTIVATION;

ANIMALS; ANNEXIN A1; ANTI-INFLAMMATORY AGENTS; GLUCOCORTICOIDS; HUMANS; MICE; MICE, MUTANT STRAINS; MODELS, BIOLOGICAL; PROTEIN MULTIMERIZATION; RECEPTORS, GLUCOCORTICOID; RESPONSE ELEMENTS; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION;

EID: 84874585409     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2012-2045     Document Type: Review

References (186)

1. Beato M, Klug J. Steroid hormone receptors: An update. Hum Reprod Update. 2000;6:225-236.
2. Boumpas DT, Chrousos GP, Wilder RL, Cupps TR, Balow JE. Glucocorticoid therapy for immune-mediated diseases: Basic and clinical correlates. Ann Intern Med. 1993;119:1198-1208.
3. Schmid W, Cole TJ, Blendy JA, Schutz G. Molecular genetic analysis of glucocorticoid signalling in development. J Steroid Biochem Mol Biol. 1995;53:33-35.
4. Prigent H, Maxime V, Annane D. Clinical review: Corticotherapy in sepsis. Crit Care. 2004;8:122-129.
5. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids-new mechanisms for old drugs.NEngl JMed. 2005;353:1711-1723.
6. McDonough AK, Curtis JR, Saag KG. The epidemiology of glucocorticoid-associated adverse events. Curr Opin Rheumatol. 2008;20:131-137.
7. Schacke H, Docke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther. 2002;96:23-43.
8. Whitfield GK, Jurutka PW, Haussler CA, Haussler MR. Steroid hormone receptors: Evolution, ligands, and molecular basis of biologic function. J Cell Biochem. 1999;Suppl 32-33:110-122.
9. Beck IM, Vanden Berghe W, Gerlo S, et al. Glucocorticoids and mitogen-and stress-activated protein kinase 1 inhibitors: Possible partners in the combat against inflammation. Biochem Pharmacol. 2009;77:1194-1205.
10. Frijters R, Fleuren W, Toonen EJ, et al. Prednisolone-induced differential gene expression in mouse liver carrying wild type or a dimerization-defective glucocorticoid receptor. BMC Genomics. 2010;11:359.
11. Reichardt HM, Kaestner KH, Tuckermann JG, et al.DNAbinding of the glucocorticoid receptor is not essential for survival. Cell. 1998;93:531-541.
12. De Kloet ER, Derijk R. Signaling pathways in brain involved in predisposition and pathogenesis of stress-related disease: Genetic and kinetic factors affecting the MR/GR balance. Ann NY Acad Sci. 2004;1032:14-34.
13. Fiebeler A, Muller DN, Shagdarsuren E, Luft FC. Aldosterone, mineralocorticoid receptors, and vascular inflammation. Curr Opin Nephroland Hypertens. 2007;16:134-142.
14. Funder JW. Mineralocorticoid-receptor blockade, hypertension and heart failure. Nature Clin Pract Endocrinol Metab. 2005;1: 4-5.
15. Vandevyver S, Dejager L, Libert C. On the trail of the glucocorticoid receptor: Into the nucleus and back. Traffic. 2012;13:364-374.
16. Cheung J, Smith DF. Molecular chaperone interactions with steroid receptors: An update. Mol Endocrinol. 2000;14:939-946.
17. Pratt WB, Toft DO. Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr Rev. 1997;18: 306-360.
18. Baschant U, Lane NE, Tuckermann J. The multiple facets of glucocorticoid action in rheumatoid arthritis. Nat rev Rheumatol. 2012;8:645-655.
19. Zhou J, Cidlowski JA. The human glucocorticoid receptor: One gene, multiple proteins and diverse responses. Steroids. 2005;70: 407-417.
20. Uhlenhaut NH, Barish GD, Yu RT, et al. 2012 Insights into negative regulation by the glucocorticoid receptor from genome-wide profiling of inflammatory cistromes. Mol cell
21. Vanderbilt JN, Miesfeld R, Maler BA, Yamamoto KR. Intracellular receptor concentration limits glucocorticoid-dependent enhancer activity. Mol Endocrinol. 1987;1:68-74.
22. LiddleGW.Analysis of circadian rhythms inhumanadrenocortical secretory activity. Arch Intern Med. 1966;117:739-743.
23. Qian X, Droste SK, Lightman SL, Reul JM, Linthorst AC. Circadian and ultradian rhythms of free glucocorticoid hormone are highly synchronized between the blood, the subcutaneous tissue, and the brain. Endocrinology. 2012;153:4346-4353.
24. Veldhuis JD, Iranmanesh A, Lizarralde G, Johnson ML. Amplitude modulation of a burstlike mode of cortisol secretion subserves the circadian glucocorticoid rhythm. Am J Physiol. 1989;257:E6-E14.
25. Schmid W, Strahle U, Schutz G, Schmitt J, Stunnenberg H. Glucocorticoid receptor binds cooperatively to adjacent recognition sites. EMBO J. 1989;8:2257-2263.
26. Schena M, Freedman LP, Yamamoto KR. Mutations in the glucocorticoid receptor zinc finger region that distinguish interdigitated DNA binding and transcriptional enhancement activities. Genes Dev. 1989;3:1590-1601.
27. Strahle U, Klock G, Schutz G. A DNA sequence of 15 base pairs is sufficient to mediate both glucocorticoid and progesterone induction of gene expression. Proc Natl Acad Sci USA. 1987;84:7871-7875.
28. Lefstin JA, Yamamoto KR. Allosteric effects of DNA on transcriptional regulators. Nature. 1998;392:885-888.
29. Meijsing SH, PufallMA,So AY, Bates DL, Chen L,YamamotoKR. DNA binding site sequence directs glucocorticoid receptor structure and activity. Science. 2009;324:407-410.
30. Voss TC, Schiltz RL, Sung MH, et al. Dynamic exchange at regulatory elements during chromatin remodeling underlies assisted loading mechanism. Cell. 2011;146:544-554.
31. De Bosscher K, Haegeman G. 2009 Minireview: Latest perspectives on antiinflammatory actions of glucocorticoids. Mol Endocrinol. 2009 23(3):281-291
32. McNally JG, Muller WG, Walker D, Wolford R, Hager GL. The glucocorticoid receptor: Rapid exchange with regulatory sites in living cells. Science. 2000;287:1262-1265.
33. Dostert A, Heinzel T. Negative glucocorticoid receptor response elements and their role in glucocorticoid action. Curr Pharm Des. 2004;10:2807-2816.
34. Morrison N, Eisman J. Role of the negative glucocorticoid regulatory element in glucocorticoid repression of the human osteocalcin promoter. J Bone Miner Res. 1993;8:969-975.
35. Surjit M, Ganti KP, Mukherji A, et al. Widespread negative response elements mediate direct repression by agonist-liganded glucocorticoid receptor. Cell. 2011;145:224-241.
36. Garside H, Stevens A, Farrow S, et al. Glucocorticoid ligands specify different interactions with NF-K B by allosteric effects on the glucocorticoid receptor DNA binding domain. J Biol Chem. 2004; 279:50050-50059.
37. Scheinman RI, Gualberto A, JewellCM,Cidlowski JA, BaldwinAS Jr. Characterization of mechanisms involved in transrepression of NF-β B by activated glucocorticoid receptors. Mol Cell Biol. 1995; 15:943-953.
38. Karin M.Newtwists in gene regulation by glucocorticoid receptor: Is DNA binding dispensable? Cell. 1998;93:487-490.
39. Kassel O, Herrlich P. Crosstalk between the glucocorticoid receptor and other transcription factors: Molecular aspects. Mol Cell Endocrinol. 2007;275:13-29.
40. De Bosscher K. Selective glucocorticoid receptor modulators. J Steroid Biochem Mol Biol. 2010;120:96-104.
41. Newton R, Holden NS, Catley MC, et al. Repression of inflammatory gene expression in human pulmonary epithelial cells by small-molecule IK Bkinase inhibitors. J Pharmacol Exp Ther. 2007; 321:734-742.
42. De Bosscher K, Haegeman G, Elewaut D. Targeting inflammation using selective glucocorticoid receptor modulators. Curr Opin Pharmacol. 2010;10:497-504.
43. Doggrell S. Is AL-438 likely to have fewer side effects than the glucocorticoids? Expert Opin Investig Drugs. 2003;12:1227-1229.
44. Miner JN, Ardecky B, Benbatoul K, et al. Antiinflammatory glucocorticoid receptor ligand with reduced side effects exhibits an altered protein-protein interaction profile. Proc Natl Acad Sci USA. 2007;104:19244-19249.
45. Schacke H, Rehwinkel H, Asadullah K. Dissociated glucocorticoid receptor ligands: Compounds with an improved therapeutic index. Curr Opin Investig Drugs. 2005;6:503-507.
46. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS Jr. Role of transcriptional activation of I K B α in mediation of immunosuppression by glucocorticoids. Science. 1995;270:283-286.
47. Clark AR. Anti-inflammatory functions of glucocorticoid-induced genes. Mol Cell Endocrinol. 2007;275:79-97.
48. van Raalte DH, Ouwens DM, Diamant M. Novel insights into glucocorticoid-mediated diabetogenic effects: Towards expansion of therapeutic options? Eur j clin investig. 2009;39:81-93.
49. Tuckermann JP, Reichardt HM, Arribas R, et al. The DNA binding-independent function of the glucocorticoid receptor mediates repression of AP-1-dependent genes in skin. J Cell Biol. 1999;147: 1365-1370.
50. Heck S, Bender K, Kullmann M, Gottlicher M, Herrlich P, Cato AC. I K B α-independent downregulation of NF-K B activity by glucocorticoid receptor. Embo J. 1997;16:4698-4707.
51. Heck S, Kullmann M, Gast A, et al. A distinct modulating domain in glucocorticoid receptor monomers in the repression of activity of the transcription factor AP-1. EMBO J. 1994;13:4087-4095.
52. Ogawa S, Lozach J, Benner C, et al. Molecular determinants of crosstalk between nuclear receptors and toll-like receptors. Cell. 2005;122:707-721.
53. ReilyMM,Pantoja C, Hu X, Chinenov Y, Rogatsky I. The GRIP1: IRF3 interaction as a target for glucocorticoid receptor-mediated immunosuppression. Embo J. 2006;25:108-117.
54. Smoak KA, Cidlowski JA. Mechanisms of glucocorticoid receptor signaling during inflammation. Mech Ageing Dev. 2004;125:697-706.
55. Glass CK, Saijo K. Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells. Nat Rev Immunol. 2010;10:365-376.
56. Baschant U, Frappart L, Rauchhaus U, et al. Glucocorticoid therapy of antigen-induced arthritis depends on the dimerized glucocorticoid receptor in T cells. Proc Natl Acad Sci USA. 2011;108: 19317-19322.
57. Kleiman A, Hubner S, Rodriguez Parkitna JM, et al. Glucocorticoid receptor dimerization is required for survival in septic shock via suppression of interleukin-1 in macrophages. Faseb J. 2012; 26:722-729.
58. Tuckermann JP, Kleiman A, Moriggl R, et al. Macrophages and neutrophils are the targets for immune suppression by glucocorticoids in contact allergy. J Clin Invest. 2007;117:1381-1390.
59. Vandevyver S, Dejager L, Van Bogaert T, et al. Glucocorticoid receptor dimerization induces MKP1 to protect against TNF-induced inflammation. J Clin Invest. 2012;122:2130-2140.
60. Reichardt HM, Tuckermann JP, Gottlicher M, et al. Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor. Embo J. 2001;20:7168-7173.
61. Jewell CM, Scoltock AB, Hamel BL, Yudt MR, Cidlowski JA. Complexhumanglucocorticoid receptor dim mutations define glucocorticoid induced apoptotic resistance in bone cells. Mol Endocrinol. 2012;26:244-256.
62. Savory JG, Prefontaine GG, Lamprecht C, et al. Glucocorticoid receptor homodimers and glucocorticoid-mineralocorticoid receptor heterodimers form in the cytoplasm through alternative dimerization interfaces. Mol Cell Biol. 2001;21:781-793.
63. Bledsoe RK, Montana VG, Stanley TB, et al. Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition. Cell. 2002;110:93-105.
64. Cole TJ, Blendy JA,MonaghanAP, et al. Targeted disruption of the glucocorticoid receptor gene blocks adrenergic chromaffin cell development and severely retards lung maturation. Genes Dev. 1995; 9:1608-1621.
65. Oitzl MS, Reichardt HM, Joels M, de Kloet ER. Point mutation in the mouse glucocorticoid receptor preventing DNA binding impairs spatial memory. Proc Natl Acad Sci USA. 2001;98:12790-12795.
66. Asada M, Rauch A, Shimizu H, et al. DNA binding-dependent glucocorticoid receptor activity promotes adipogenesis via Kruppel-like factor 15 gene expression. Lab Invest. 2011;91:203-215.
67. Bayo P, Sanchis A, Bravo A, et al. Glucocorticoid receptor is required for skin barrier competence. Endocrinology. 2008;149: 1377-1388.
68. Ehrchen J, Steinmuller L, Barczyk K, et al. Glucocorticoids induce differentiation of a specifically activated, anti-inflammatory subtype of human monocytes. Blood. 2007;109:1265-1274.
69. Dickinson RJ, Keyse SM. Diverse physiological functions for dualspecificity MAP kinase phosphatases. J Cell Sci. 2006;119:4607-4615.
70. Jeffrey KL, Camps M, Rommel C, Mackay CR. Targeting dualspecificity phosphatases: Manipulating MAP kinase signalling and immune responses. Nat Rev Immunol. 2007;6:391-403.
71. Alessi DR, Smythe C, Keyse SM. The human CL100 gene encodes a Tyr/Thr-protein phosphatase which potently and specifically inactivates MAP kinase and suppresses its activation by oncogenic ras in Xenopus oocyte extracts. Oncogene. 1993;8:2015-2020.
72. Sun H, Charles CH, Lau LF, Tonks NK. MKP-1 (3CH134), an immediate early gene product, is a dual specificity phosphatase that dephosphorylates MAP kinase in vivo. Cell. 1993;75:487-493.
73. Franklin CC, Kraft AS. Conditional expression of the mitogenactivated protein kinase (MAPK) phosphatase MKP-1 preferentially inhibits p38 MAPK and stress-activated protein kinase in U937 cells. J Biol Chem. 1997;272:16917- 16923.
74. Liu Y, Gorospe M, Yang C, Holbrook NJ. Role of mitogen-activated protein kinase phosphatase during the cellular response to genotoxic stress. Inhibition of c-Jun N-terminal kinase activity and AP-1-dependent gene activation. J Biol Chem. 1995;270:8377-8380.
75. Raingeaud J, Gupta S, Rogers JS, et al. Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine. J Biol Chem. 1995;270:7420-7426.
76. Hutter D, Chen P, Barnes J, Liu Y. Catalytic activation of mitogenactivated protein (MAP) kinase phosphatase-1 by binding to p38 MAP kinase: Critical role of the p38 C-terminal domain in its negative regulation. Biochem J. 2000;352 Pt. 1:155-163.
77. Reddy TE, Pauli F, Sprouse RO, et al. Genomic determination of the glucocorticoid response reveals unexpected mechanisms of gene regulation. Genome Res. 2009;19:2163-2171.
78. Shipp LE, Lee JV, Yu CY, et al. Transcriptional regulation of human dual specificity protein phosphatase 1 (DUSP1) gene by glucocorticoids. PLoS One. 2010;5:e13754.
79. Abraham SM, Lawrence T, Kleiman A, et al. Antiinflammatory effects of dexamethasone are partly dependent on induction of dual specificity phosphatase 1. J Exp Med. 2006;203:1883-1889.
80. Bhattacharyya S, Brown DE, Brewer JA, Vogt SK, Muglia LJ. Macrophage glucocorticoid receptors regulate Toll-like receptor 4-mediated inflammatory responses by selective inhibition of p38 MAP kinase. Blood. 2007;109:4313-4319.
81. Wang X, Nelin LD, Kuhlman JR, Meng X, Welty SE, Liu Y. The role of MAP kinase phosphatase-1 in the protective mechanism of dexamethasone against endotoxemia. Life Sci. 2008;83:671-680.
82. Canterini S, Bosco A, De Matteis V, Mangia F, Fiorenza MT. THG-1pit moves to nucleus at the onset of cerebellar granule neurons apoptosis. Mol Cell Neurosci. 2009;40:249-257.
83. D'Adamio F, Zollo O, Moraca R, et al. A new dexamethasoneinduced gene of the leucine zipper family protects T lymphocytes from TCR/CD3-activated cell death. Immunity. 1997;7:803-812.
84. Shibanuma M, Kuroki T, Nose K. Isolation of a gene encoding a putative leucine zipper structure that is induced by transforming growth factor α 1 and other growth factors. J Biol Chem. 1992; 267:10219-10224.
85. Rauch A, Seitz S, Baschant U, et al. Glucocorticoids suppress bone formation by attenuating osteoblast differentiation via the monomeric glucocorticoid receptor. Cell Metab. 2010;11:517-531.
86. Ayroldi E, Migliorati G, Bruscoli S, et al. Modulation of T-cell activation by the glucocorticoid-induced leucine zipper factor via inhibition of nuclear factor K B. Blood. 2001;98:743-753.
87. Ayroldi E, Zollo O, Macchiarulo A, Di Marco B, Marchetti C, Riccardi C. Glucocorticoid-induced leucine zipper inhibits the Rafextracellular signal-regulated kinase pathway by binding to Raf-1. Mol Cell Biol. 2002;22:7929-7941.
88. Katz ME, McCormick F. Signal transduction from multiple Ras effectors. Curr Opin Genet Dev. 1997;7:75-79.
89. Malumbres M, Barbacid M.RASoncogenes: The first 30 years. Nat Rev Immunol. 2003;3:459-465.
90. Vojtek AB, Der CJ. Increasing complexity of the Ras signaling pathway. J Biol Chem. 1998;273:19925-19928.
91. Mittelstadt PR, Ashwell JD. Inhibition of AP-1 by the glucocorticoid-inducible protein GILZ. J Biol Chem. 2001;276:29603- 29610.
92. Cannarile L, Cuzzocrea S, Santucci L, et al. Glucocorticoid-induced leucine zipper is protective in Th1-mediated models of colitis. Gastroenterology. 2009;136:530-541.
93. Beaulieu E, Ngo D, Santos L, et al. Glucocorticoid-induced leucine zipper is an endogenous antiinflammatory mediator in arthritis. Arthritis Rheum. 2010;62:2651-2661.
94. Srinivasan M, Janardhanam S. Novel p65 binding glucocorticoidinduced leucine zipper peptide suppresses experimental autoimmune encephalomyelitis. J Biol Chem. 2011;286:44799-44810.
95. Eddleston J, Herschbach J, Wagelie-Steffen AL, Christiansen SC, Zuraw BL. The anti-inflammatory effect of glucocorticoids is mediated by glucocorticoid-induced leucine zipper in epithelial cells. J Allergy Clin Immunol. 2007;119:115-122.
96. Mathurin P, Deng QG, Keshavarzian A, Choudhary S, Holmes EW, Tsukamoto H. Exacerbation of alcoholic liver injury by enteral endotoxin in rats. Hepatology. 2000;32:1008-1017.
97. Gerke V, Moss SE. Annexins: From structure to function. Physiol Rev. 2002;82:331-371.
98. Kovacic RT, Tizard R, Cate RL, Frey AZ, Wallner BP. Correlation of gene and protein structure of rat and human lipocortin I. Biochemistry. 1991;30:9015-9021.
99. Blackwell GJ, Carnuccio R, Di Rosa M, Flower RJ, Parente L, Persico P. Macrocortin: A polypeptide causing the anti-phospholipase effect of glucocorticoids. Nature. 1980;287:147-149.
100. Liu J, Munoz NM, Meliton AY, et al. β2-Integrin adhesion caused by eotaxin but not IL-5 is blocked by PDE-4 inhibition and β2-adrenoceptor activation in human eosinophils. Pulm Pharmacol Ther. 2004;17:73-79.
101. Perretti M, D'Acquisto F. Annexin A1 and glucocorticoids as effectors of the resolution of inflammation. Nat Rev Immunol. 2009; 9:62-70.
102. Wang ZM, Zhu SG, Wu ZW, Lu Y, Fu HZ, Qian RQ. Kirenol upregulates nuclear annexin-1 which interacts with NF-K B to attenuate synovial inflammation of collagen-induced arthritis in rats. J Ethnopharmacol. 2011;137:774-782.
103. Zhang Z, Huang L, Zhao W, Rigas B. Annexin 1 induced by antiinflammatory drugs binds to NF-K B and inhibits its activation: Anticancer effects in vitro and in vivo. Cancer Res. 2010;70:2379-2388.
104. D'Amico M, Di Filippo C, La M, et al. Lipocortin 1 reduces myocardial ischemia-reperfusion injury by affecting local leukocyte recruitment. FASEB J. 2000;14:1867-1869.
105. Damazo AS, Sampaio AL, Nakata CM, Flower RJ, Perretti M, Oliani SM. Endogenous annexin A1 counter-regulates bleomycininduced lung fibrosis. BMC Immunol. 2011;12:59.
106. Vong L, Ferraz JG, Dufton N, et al. Up-regulation of Annexin-A1 and lipoxin A(4) in individuals with ulcerative colitis may promote mucosal homeostasis. PLoS One. 2012;7:e39244.
107. Yang YH, Morand EF, Getting SJ, et al. Modulation of inflammation and response to dexamethasone by Annexin 1 in antigeninduced arthritis. Arthritis Rheum. 2004;50:976-984.
108. Babbin BA, Laukoetter MG, Nava P, et al. Annexin A1 regulates intestinal mucosal injury, inflammation, and repair. J Immunol. 2008;181:5035-5044.
109. Oliani SM, Ciocca GA, Pimentel TA, Damazo AS, Gibbs L, Perretti M. Fluctuation of annexin-A1 positive mast cells in chronic granulomatous inflammation. Inflamm Res. 2008;57:450-456.
110. Yang Y, Hutchinson P, Morand EF. Inhibitory effect of annexin I on synovial inflammation in rat adjuvant arthritis. Arthritis Rheum. 1999;42:1538-1544.
111. Martin GR, Perretti M, Flower RJ, Wallace JL. Annexin-1 modulates repair of gastric mucosal injury. Am J Physiol Endocrinol Metab. 2008;294:G764-G769.
112. Ouyang N, Zhu C, Zhou D, et al. MC-12, an Annexin A1-based peptide, is effective in the treatment of experimental colitis. PLoS One. 2012;7:e41585.
113. Tischner D, Reichardt HM. Glucocorticoids in the control of neuroinflammation. Mol Cell Endocrinol. 2007;275:62-70.
114. Ruzek MC, Pearce BD, Miller AH, Biron CA. Endogenous glucocorticoids protect against cytokine-mediated lethality during viral infection. J Immunol. 1999;162:3527-3533.
115. Galon J, Franchimont D, Hiroi N, et al. Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells. Faseb J. 2002;16:61-71.
116. Diefenbacher M, Sekula S, Heilbock C, et al. Restriction to Fos family members of Trip6-dependent coactivation and glucocorticoid receptor-dependent trans-repression of activator protein-1. Mol Endocrinol. 2008;22:1767-1780.
117. Buttgereit F, Zhou H, Kalak R, et al. Transgenic disruption of glucocorticoid signaling in mature osteoblasts and osteocytes attenuates K/BxN mouse serum-induced arthritis in vivo. Arthritis Rheum. 2009;60:1998-2007.
118. Hermoso MA, Matsuguchi T, Smoak K, Cidlowski JA. Glucocorticoids and tumor necrosis factor α cooperatively regulate toll-like receptor 2 gene expression. Mol Cell Biol. 2004;24:4743-4756.
119. McMaster A, Ray DW. Modelling the glucocorticoid receptor and producing therapeutic agents with anti-inflammatory effects but reduced side-effects. Exp Physiol. 2007;92:299-309.
120. Reber LL, Daubeuf F, Plantinga M, et al. A dissociated glucocorticoid receptor modulator reduces airway hyperresponsiveness and inflammation in a mouse model of asthma. J Immunol. 2012;188: 3478-3487.
121. Rosen J, Miner JN. The search for safer glucocorticoid receptor ligands. Endocr Rev. 2005;26:452-464.
122. Kleiman A, Tuckermann JP. Glucocorticoid receptor action in beneficial and side effects of steroid therapy: Lessons from conditional knockout mice. Mol Cell Endocrinol. 2007;275:98-108.
123. Grose R, Werner S, Kessler D, et al. A role for endogenous glucocorticoids in wound repair. EMBO Rep. 2002;3:575-582.
124. Reichardt SD, Foller M, Rexhepaj R, et al. Glucocorticoids enhance intestinal glucose uptake via the dimerized glucocorticoid receptor in enterocytes. Endocrinology. 2012;153:1783-1794.
125. Conaway HH, Pirhayati A, Persson E, et al. Retinoids stimulate periosteal bone resorption by enhancing the protein RANKL, a response inhibited by monomeric glucocorticoid receptor. J Biol Chem. 2011;286:31425-31436.
126. Waddell DS, Baehr LM, van den Brandt J, et al. The glucocorticoid receptor and FOXO1 synergistically activate the skeletal muscle atrophy-associated MuRF1 gene.AmJ Physiol Endocrinol Metab. 2008;295:E785-E797.
127. De Bosscher K, Vanden Berghe W, Beck IM, et al. A fully dissociated compound of plant origin for inflammatory gene repression. Proc Natl Acad Sci USA. 2005;102:15827-15832.
128. Bosmann M, Grailer JJ, Zhu K, et al. Anti-inflammatory effects of β2 adrenergic receptor agonists in experimental acute lung injury. Faseb J. 2012;26:2137-2144.
129. Bauvois B, Dauzonne D. Aminopeptidase-N/CD13 (EC 3.4.11.2) inhibitors: Chemistry, biological evaluations, and therapeutic prospects. Medicinal Res Rev. 2006;26:88-130.
130. Coon S, Kekuda R, Saha P, Sundaram U. Glucocorticoids differentially regulate Na-bile acid cotransport in normal and chronically inflamed rabbit ileal villus cells. Am J Physiol Endocrinol Metab. 2010;298:G675-G682.
131. Davie RJ, Hosie KB, Grobler SP, Newbury-Ecob RA, Keighley MR, Birch NJ. Ileal bile acid malabsorption in colonic Crohn's disease. Br J Surg. 1994;81:289-290.
132. Jung D, Fantin AC, Scheurer U, Fried M, Kullak-Ublick GA. Human ileal bile acid transporter gene ASBT (SLC10A2) is transactivated by the glucocorticoid receptor. Gut. 2004;53:78-84.
133. Cato AC, Geisse S, Wenz M, Westphal HM, Beato M. The nucleotide sequences recognized by the glucocorticoid receptor in the rabbit uteroglobin gene region are located far upstream from the initiation of transcription. Embo J. 1984;3:2771-2778.
134. Hagen G, Wolf M, Katyal SL, Singh G, Beato M, Suske G. Tissuespecific expression, hormonal regulation and 5'-flanking gene region of the rat Clara cell 10 kDa protein: Comparison to rabbit uteroglobin. Nucleic Acids Res. 1990;18:2939-2946.
135. Jantzen K, Fritton HP, Igo-Kemenes T, et al. Partial overlapping of binding sequences for steroid hormone receptors and DNaseI hypersensitive sites in the rabbit uteroglobin gene region. Nucleic Acids Res. 1987;15:4535-4552.
136. Lesur O, Bernard A, Arsalane K, et al. Clara cell protein (CC-16) induces a phospholipase A2-mediated inhibition of fibroblast migration in vitro. Am J Respir Crit Care Med. 1995;152:290-297.
137. Mahtani KR, Brook M, Dean JL, Sully G, Saklatvala J, Clark AR. Mitogen-activated protein kinase p38 controls the expression and posttranslational modification of tristetraprolin, a regulator of tumor necrosis factor α mRNA stability. Mol Cell Biol. 2001;21: 6461-6469.
138. Mukherjee AB, Kundu GC, Mandal AK, Pattabiraman N, Yuan CJ, Zhang Z. Uteroglobin: Physiological role in normal glomerular function uncovered by targeted disruption of the uteroglobin gene in mice. Am J Kidney Dis. 1998;32:1106-1120.
139. Mukherjee AB, Zhang Z, Chilton BS. Uteroglobin: A steroid-inducible immunomodulatory protein that founded the Secretoglobin superfamily. Endocr Rev. 2007;28:707-725.
140. Hogger P, Erpenstein U, Rohdewald P, Sorg C. Biochemical characterization of a glucocorticoid-induced membrane protein (RM3/1) in human monocytes and its application as model system for ranking glucocorticoid potency. Pharm Res. 1998;15: 296-302.
141. Kowal K, Silver R, Slawinska E, Bielecki M, Chyczewski L, Kowal-Bielecka O. CD163 and its role in inflammation. Folia Histochem Cytobiol. 2011;49:365-374.
142. Schaer DJ, Boretti FS, Hongegger A, et al. Molecular cloning and characterization of the mouse CD163 homologue, a highly glucocorticoid-inducible member of the scavenger receptor cysteine-rich family. Immunogenetics. 2001;53:170-177.
143. Schaer DJ, Boretti FS, Schoedon G, Schaffner A. Induction of the CD163-dependent haemoglobin uptake by macrophages as a novel anti-inflammatory action of glucocorticoids. Br J Haematol. 2002; 119:239-243.
144. Young JD, Lawrence AJ, MacLean AG, et al. Thymosin β 4 sulfoxide is an anti-inflammatory agent generated by monocytes in the presence of glucocorticoids. Nat Med. 1999;5:1424-1427.
145. Graham TE, Key TA, Kilpatrick K, Dorin RI. Dexras1/AGS-1, a steroid hormone-induced guanosine triphosphate-binding protein, inhibits 3',5'-cyclic adenosine monophosphate-stimulated secretion in AtT-20 corticotroph cells. Endocrinology. 2001;142:2631-2640.
146. Graham TE, Prossnitz ER, Dorin RI. Dexras1/AGS-1 inhibits signal transduction from the Gi-coupled formyl peptide receptor to Erk-1/2 MAP kinases. J Biol Chem. 2002;277:10876-10882.
147. Kemppainen RJ, Behrend EN. Dexamethasone rapidly induces a novel ras superfamily member-related gene in AtT-20 cells. J Biol Chem. 1998;273:3129-3131.
148. Nguyen CH, Watts VJ. Dexamethasone-induced Ras protein 1 negatively regulates protein kinase C delta: Implications for adenylyl cyclase 2 signaling. Mol Pharmacol. 2006;69:1763-1771.
149. Hiragun T, Peng Z, Beaven MA. Dexamethasone up-regulates the inhibitory adaptor protein Dok-1 and suppresses downstream activation of the mitogen-activated protein kinase pathway in antigen-stimulated RBL-2H3 mast cells. Mol Pharmacol. 2005;67: 598-603.
150. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003;4:330-336.
151. Karagiannidis C, Akdis M, Holopainen P, et al. Glucocorticoids upregulate FOXP3 expression and regulatory T cells in asthma. J Allergy Clin Immunol. 2004;114:1425-1433.
152. Gayo A, Mozo L, Suarez A, Tunon A, Lahoz C, Gutierrez C. Glucocorticoids increase IL-10 expression in multiple sclerosis patients with acute relapse. J Neuroimmunol. 1998;85:122-130.
153. Verhoef CM, van Roon JA, Vianen ME, Lafeber FP, Bijlsma JW. The immune suppressive effect of dexamethasone in rheumatoid arthritis is accompanied by upregulation of interleukin 10 and by differential changes in interferon gamma and interleukin 4 production. Ann Rheum Dis. 1999;58:49-54.
154. Neumann D, Kollewe C, Martin MU, Boraschi D. The membrane form of the type II IL-1 receptor accounts for inhibitory function. J Immunol. 2000;165:3350-3357.
155. Re F, Muzio M, De Rossi M, et al. The type II -receptor- as a decoy target for interleukin 1 in polymorphonuclear leukocytes: Characterization of induction by dexamethasone and ligand binding properties of the released decoy receptor. J Exp Med. 1994;179:739-743.
156. Levine SJ, Benfield T, Shelhamer JH. Corticosteroids induce intracellular interleukin-1 receptor antagonist type I expression by a human airway epithelial cell line.AmJ Respir Cell Mol Biol. 1996; 15:245-251.
157. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: Inhibition of NF-β B activity through induction of I β B synthesis. Science. 1995;270:286-290.
158. Deroo BJ, Archer TK. Glucocorticoid receptor activation of the I K B α promoter within chromatin. Mol Biol Cell. 2001;12:3365- 3374.
159. Das H, Kumar A, Lin Z, et al. Kruppel-like factor 2 (KLF2) regulates proinflammatory activation of monocytes. Proc Natl Acad Sci USA. 2006;103:6653-6658.
160. Chivers JE, Gong W, King EM, et al. Analysis of the dissociated steroid RU24858 does not exclude a role for inducible genes in the anti-inflammatory actions of glucocorticoids. Mol Pharmacol. 2006;70:2084-2095.
161. Yao XL, Cowan MJ, Gladwin MT, Lawrence MM, Angus CW, Shelhamer JH. Dexamethasone alters arachidonate release from human epithelial cells by induction of p11 protein synthesis and inhibition of phospholipase A2 activity. J Biol Chem. 1999;274: 17202-17208.
162. Zhang L, Li H, Hu X, Li XX, Smerin S, Ursano R. Glucocorticoidinduced p11 over-expression and chromatin remodeling: A novel molecular mechanism of traumatic stress? Med Hypotheses. 2011; 76:774-777.
163. Samuelsson MK, Pazirandeh A, Davani B, Okret S. p57Kip2, a glucocorticoid-induced inhibitor of cell cycle progression in HeLa cells. Mol Endocrinol. 1999;13:1811-1822.
164. Hiragun T, Peng Z, Beaven MA. Cutting edge: Dexamethasone negatively regulates Syk in mast cells by up-regulating SRC-like adaptor protein. J Immunol. 2006;177:2047-2050.
165. Abbinante-Nissen JM, Simpson LG, Leikauf GD. Corticosteroids increase secretory leukocyte protease inhibitor transcript levels in airway epithelial cells. Am J Physiol. 1995;268:L601-L606.
166. Brewer BY, Malicka J, Blackshear PJ, Wilson GM. RNA sequence elements required for high affinity binding by the zinc finger domain of tristetraprolin: Conformational changes coupled to the bipartite nature of Au-rich MRNA-destabilizing motifs. J BiolChem. 2004;279:27870-27877.
167. Carrick DM, Lai WS, Blackshear PJ. The tandem CCCH zinc finger protein tristetraprolin and its relevance to cytokine mRNA turnover and arthritis. Arthritis Res Ther. 2004;6:248-264.
168. Lai WS, Carballo E, Strum JR, Kennington EA, Phillips RS, Blackshear PJ. Evidence that tristetraprolin binds to AU-rich elements and promotes the deadenylation and destabilization of tumor necrosis factor α mRNA. Mol Cell Biol. 1999;19:4311-4323.
169. Smoak K, Cidlowski JA. Glucocorticoids regulate tristetraprolin synthesis and posttranscriptionally regulate tumor necrosis factor α inflammatory signaling. Mol Cell Biol. 2006;26:9126-9135.
170. Worthington MT, Pelo JW, Sachedina MA, Applegate JL, Arseneau KO, Pizarro TT. RNA binding properties of the AU-rich element-binding recombinant Nup475/TIS11/tristetraprolin protein. J Biol Chem. 2002;277:48558-48564.
171. Ishmael FT, Fang X, Galdiero MR, et al. Role of the RNA-binding protein tristetraprolin in glucocorticoid-mediated gene regulation. J Immunol. 2008;180:8342-8353.
172. Maier JV, Brema S, Tuckermann J, et al. Dual specificity phosphatase 1 knockout mice show enhanced susceptibility to anaphylaxis but are sensitive to glucocorticoids. Mol Endocrinol. 2007; 21:2663-2671.
173. Matta R, Barnard JA, Wancket LM, et al. Knockout of Mkp-1 exacerbates colitis in Il-10-deficient mice.AmJ Physiol Endocrinol Metab. 2012;302:G1322-G1335.
174. Wu JJ, Roth RJ, Anderson EJ, et al. Mice lacking MAP kinase phosphatase-1 have enhanced MAP kinase activity and resistance to diet-induced obesity. Cell Metab. 2006;4:61-73.
175. Zhang H, Podojil JR, Luo X, Miller SD. Intrinsic and induced regulation of the age-associated onset of spontaneous experimental autoimmune encephalomyelitis. J Immunol. 2008;181:4638-4647.
176. Salojin KV,OwusuIB, Millerchip KA, PotterM,Platt KA, Oravecz T. Essential role ofMAPKphosphatase-1 in the negative control of innate immune responses. J Immunol. 2006;176:1899-1907.
177. Sartori R, Li F, Kirkwood KL.MAPkinase phosphatase-1 protects against inflammatory bone loss. J Dent Res. 2009;88:1125-1130.
178. Jin Y, Calvert TJ, Chen B, et al. Mice deficient in Mkp-1 develop more severe pulmonary hypertension and greater lung protein levels of arginase in response to chronic hypoxia. Am J Physiol Heart Circ Physiol. 2010;298:H1518-H1528.
179. Frazier WJ, Wang X, Wancket LM, et al. Increased inflammation, impaired bacterial clearance, and metabolic disruption after gramnegative sepsis in Mkp-1-deficient mice. J Immunol. 2009;183: 7411-7419.
180. Wang X, Meng X, Kuhlman JR, et al. Knockout of Mkp-1 enhances the host inflammatory responses to gram-positive bacteria. J Immunol. 2007;178:5312-5320.
181. Kaiser RA, Bueno OF, Lips DJ, et al. Targeted inhibition of p38 mitogen-activated protein kinase antagonizes cardiac injury and cell death following ischemia-reperfusion in vivo. J Biol Chem. 2004;279:15524-15530.
182. Chi H, Barry SP, Roth RJ, et al. Dynamic regulation of pro-and anti-inflammatory cytokines by MAPK phosphatase 1 (MKP-1) in innate immune responses. Proc Natl Acad Sci U S A. 2006;103: 2274-2279.
183. Hammer M, Mages J, Dietrich H, et al. Dual specificity phosphatase 1 (DUSP1) regulates a subset of LPS-induced genes and protects mice from lethal endotoxin shock. J Exp Med. 2006; 203:15-20.
184. Zhao Q, Wang X, Nelin LD, et al. MAP kinase phosphatase 1 controls innateimmuneresponses and suppresses endotoxic shock. J Exp Med. 2006;203:131-140.
185. Hammer M, Echtenachter B, Weighardt H, et al. Increased inflammation and lethality of Dusp1-/-mice in polymicrobial peritonitis models. Immunology. 2010;131:395-404.
186. Nimah M, Zhao B, Denenberg AG, et al. Contribution of MKP-1 regulation of p38 to endotoxin tolerance. Shock. 2005;23:80-87.